Amplexd Therapeutics: Innovating Non-Invasive CIN Treatments to Prevent Cervical Cancer

GAITHERSBURG, MD, May 21, 2024 – Amplexd Therapeutics, Inc. (“Amplexd” or the “Company”), a clinical-stage biotech firm driven by patient-scientist collaboration, has announced significant strides toward finalizing product development for non-invasive treatments of Cervical Intraepithelial Neoplasia (CIN) prior to initiating Phase 1/2 clinical trials. With a recent financial boost of US$2 million from an Asia-based life sciences family office, Amplexd is set to advance its mission.

Co-Founder and CEO Alia Rahman highlighted the importance of this funding, stating, “The capital will enable us to finalize development and IND submissions ahead of first-in-human clinical trials, expected to commence later this year.” This strategic investment is a pivotal moment for Amplexd as it works to reshape HPV and cervical precancer treatments with two novel topical, non-invasive therapies. These treatments aim to provide alternatives to the traditional "watch and wait" approach for low-grade CIN and invasive surgeries for high-grade CIN.

Amplexd Therapeutics, founded in 2022, has made considerable progress in women’s health, particularly in treating CIN—a condition impacting over 178 million women worldwide annually. In the US and Europe alone, approximately 5% of cervical screenings reveal abnormalities at any point, with even higher rates observed in Asia, Latin America, and Africa. CIN arises from certain high-risk types of HPV, which, if untreated, can progress to cervical cancer, the fourth leading cause of cancer death in women globally. Early intervention at the CIN stage is crucial in preventing this progression.

Rahman’s personal journey with persistent CIN was the catalyst for Amplexd's inception. After being diagnosed with carcinoma in situ (high-grade CIN) and undergoing an invasive surgery, she faced a prolonged struggle with chronic CIN over 13 years. Determined to find a non-invasive treatment, Rahman began developing a topical therapy utilizing Epigallocatechin gallate (EGCG), a polyphenol from green tea. Though EGCG's efficacy against CIN had been explored in research, it had not been sufficiently developed for commercial therapeutic use.

Amplexd Therapeutics emerged from this gap in the market. Rahman envisioned creating an alternative to invasive procedures, aiming to alleviate the psychological burden and physical trauma associated with chronic CIN. "Our non-invasive treatments have the potential to be a game-changer both in terms of access and comfort," Rahman said. "Once approved, these therapies could offer a better patient experience without compromising care quality.”

Amplexd is developing two distinct, cost-effective therapies for CIN. The first is an intravaginal suppository for low-grade CIN, while the second is a photodynamic therapy (PDT) system targeting high-grade CIN. Both treatments are designed to selectively target abnormal cells, thereby modernizing care for women in developed nations by avoiding invasive surgeries. Additionally, they aim to provide accessible, potentially life-saving care in low and middle-income regions.

Amplexd Therapeutics is committed to advancing women's health by delivering innovative, non-invasive treatments for cervical precancer.